source
- Expedition Therapeutics secures $115M Series B to advance China-origin COPD drugExpedition Therapeutics, a biotech that licenses drugs from Chinese firms, announced a $115 million Series B financing that will fund mid-stage testing of its experimental COPD candidate. The fund…
- WuXi AppTec posts six-month revenue higher than Lonza for first timeWuXi AppTec, a Chinese contract manufacturing organization, has reported that its revenue over the most recent six-month period exceeded that of Swiss CDMO Lonza for the first time. The increase c…